<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509949</url>
  </required_header>
  <id_info>
    <org_study_id>DDRT</org_study_id>
    <nct_id>NCT02509949</nct_id>
  </id_info>
  <brief_title>Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tao Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <brief_summary>
    <textblock>
      Delirium, an acute change in mental status, is a serious medical complication among
      hospitalized patients. Syndrome of delirium involves agitation, sleep disturbance, affective
      disorders and cognitive disruptions.

      One vulnerable period for developing delirium is in the postoperative days. Postoperative
      delirium often initiates a cascade of adverse consequences including an increase in length of
      stay and hospital costs, and greater mortality. The investigators have observed that the
      incidence of postoperative delirium in patients after renal transplantation is about 20-30%
      in our hospital.

      Several studies have revealed that dexmedetomidine, as a widely used sedative during
      anesthesia, can decrease the incidence of postoperative delirium after cardiac surgery. The
      investigators aim to examine whether administration of dexmedetomidine can reduce
      postoperative delirium after living donor renal transplantation in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Delirium</measure>
    <time_frame>Postoperative day 1-7.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postoperative Delirium After Living Donor Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline ivpump 0.2ug/kg/h during living donor renal transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 17 and &lt; 60 years;

          -  American Society of Anesthesiology (ASA) I-III;

          -  admitted for living donor renal transplantation.

        Exclusion Criteria:

          -  Patients with a history of drug abuse;

          -  preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase
             inhibitor, inability to communicate in the preoperative period (coma, profound
             dementia, or language barrier).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhang, Master of Medicine</last_name>
      <phone>13580482938</phone>
      <email>zhtao98@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <last_update_submitted>June 9, 2018</last_update_submitted>
  <last_update_submitted_qc>June 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Tao Zhang</investigator_full_name>
    <investigator_title>Tao Zhang</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

